Ace, if you just look at one revenue stream ( treating Nieman Pick Type C patients )and do the math: take the world wide # of people with Nieman Pick Type C x the monthly cost to treat = over a billion dollars. If you assume that CTDH will get 15% of it = $150 million per year ( I have discussed these #s with the company and they have similar projections - - they didn't say I was out of the ball park and even said I was VERY close ). Yes there is a number of things that have to happen: one of which is getting FDA approval for orphan drug status. But that is one of their top priorities. If you look at other diseases related to Nieman Pick Type C they have identified 4 others ( alzheimers, diabetes, etc. )that might also benefit. So just from on division of CTDH you could generate tens of millions ( if not hundreds of millions ) in revenue. Maybe I am too optimistic but I have been in this over 9 years and can't be more please with the recent moves they have made and their corporate priorities.
News 
Market Data 
Discover 
AI
